Teva Invests $700 Million to Acquire Innovative Tourette Syndrome Treatment
Tel Aviv, Wednesday, 29 April 2026.
Teva is acquiring Emalex Biosciences for $700 million to secure Ecopipam, a pioneering late-stage treatment for pediatric Tourette syndrome, strategically positioning the company for long-term growth.
Strategic Financials and Deal Structure
On April 29, 2026, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced a definitive agreement to purchase Emalex Biosciences [1][2]. Under the terms of the deal, Teva will pay an upfront cash sum of $700 million to Emalex shareholders upon closing [1][2]. Additionally, the agreement includes up to $200 million in potential commercial milestone payments and royalties based on global net sales of Ecopipam, contingent upon regulatory approval [1][2]. This brings the maximum potential deal value to 900 million. Teva intends to finance the initial $700 million payment utilizing its existing cash on hand [2]. Prior to the announcement, Teva’s stock closed at $31.62, with a trading volume of 8,959,658 shares [2].
Ecopipam’s Clinical Profile and Regulatory Path
The centerpiece of this acquisition is Ecopipam, an investigational, first-in-class selective dopamine D1 receptor antagonist designed to treat pediatric Tourette syndrome [1][2]. Ecopipam operates by blocking the D1 and D5 family of receptors, differentiating it from existing therapies [1]. In 2025, Emalex announced positive topline results from a Phase 3 pediatric study, demonstrating statistical significance for the primary efficacy endpoint—time to relapse—with a p-value of 0.0084 [1][2]. Clinical data indicated that the most common adverse events included somnolence at 10.2%, insomnia at 7.4%, anxiety at 6.0%, fatigue at 5.6%, and headache at 5.1% [1][2].
Origins, Execution, and Closing Timelines
Emalex Biosciences was originally founded by Paragon Biosciences, a firm known for advancing companies with proven science to late-stage readiness [1]. Jeff Aronin, CEO of Paragon Biosciences and Chairman of Emalex, highlighted that the company was built around a distinct patient need, utilizing precision and speed to bring Ecopipam to its current state [1][2]. Aronin echoed the sentiment that Teva’s expertise is the optimal vehicle to execute the global commercialization of the drug [1][2].